In summary, a possible explanation for the roles of K18 in breast cancer is that K18 is increased in the early stage of cancer cells to proliferate and avoid immune apoptosis; as the disease progresses it downregulates to promote invasion and metastasis, drug resistance, and malignancy. This evidence concerns the gene KRT18 and cancer.